Harpoon Therapeutics Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Total Funding:$223.2M
Lead Investor(s):OrbiMed
Claim your profile

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Harpoon Therapeutics's estimated annual revenue is currently $4.8M per year.
  • Harpoon Therapeutics received $70.0M in venture funding in November 2018.
  • Harpoon Therapeutics's estimated revenue per employee is $71,970
  • Harpoon Therapeutics's total funding is $223.2M.

Employee Data

  • Harpoon Therapeutics has 66 Employees.
  • Harpoon Therapeutics grew their employee count by 27% last year.
  • Harpoon Therapeutics currently has 7 job openings.

Executive Contacts

Mark WessonDirector, CMC Outsourcing
Phyllis KimmelAdministrative Manager
Natalie SacksChief Medical Officer
Suresh PullelaSenior Director Quality Assurance
Che-Leung LawVP, Translational Medicine
Rupak NeupaneSenior Manager, Corporate Analytics
Georgia ErbezChief Financial Officer
Christopher WhitmoreVice President Finance
Rachael LesterVP Corporate Development
Jack LinDirector, New Technologies

Harpoon Therapeutics is a clinical stage biotechnology company co-founded by Patrick Bauerle, a pioneer in T-cell engagement, and Luke Evnin (MPM Capital) in 2015 to develop and commercialize a novel class of T cell recruiting antibodies engage a patient's own immune cells to fight cancer and other diseases. The world-class team of protein engineers and immunologists at Harpoon have built upon the successful development of the bispecific (BiTE or bispecific T cell engager) antibody Blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. Harpoon's tri-specific T-cell redirection platform -- TriTAC -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, CAR-T and other T-cell engaging approaches by improving activity against solid tumors convenience of administration treatment of more tumor types and other immunologic diseases. Harpoon has discovered proprietary drug candidates and has an expansive research portfolio leveraging the TriTAC platform. Harpoon plans to file its first 2 INDs and initiate its first clinical study in 2018. Harpoon Therapeutics recently completed a Series B financing round with investors: MPM Capital, New Leaf Venture Partners, Arix Biosciences, and Taiho Ventures.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
Rancho BioScien...
Tlc Pharmacy
Otsuka America
endpoint Clinic...
Pliant Therapeu...
ZO Skin Health
Teledyne Hanson...
Greenwich Biosc...

Harpoon Therapeutics News

09/03/2019 - Harpoon Therapeutics to Participate in Two Upcoming ...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage ...

09/08/2019 - Analysts Expect Harpoon Therapeutics (HARP) Stock to Rise 74%; Rated Strong Buy

Harpoon Therapeutics Inc (HARP) stock has fallen -2.14% since Thursday, February 7, 2019 when Harpoon Therapeutics Inc began trading.

09/03/2019 - Harpoon Therapeutics, Inc. (HARP) Fell By -1.0%, And Here's Why

In its latest trading session, Harpoon Therapeutics, Inc. (HARP) dropped by -1.0% – here is what that looked like (as of 2019-09-06): ...

Harpoon Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-05-26$45.0MBArix BioscienceArticle

Harpoon Therapeutics Executive Hires

2017-05-05Che-Leung LawVP TRANSLATIONAL MEDICINEArticle
2017-10-27Susan JonesSVP product developmentArticle
2018-09-19Chris WhitmoreVP FinanceArticle
2018-10-04Natalie SacksChief Medical OfficerArticle
2018-10-31Georgia ErbezChief Financial OfficerArticle